Neoadjuvant weekly paclitaxel (wP) and carboplatin (Cb) with trastuzumab (T) and pertuzumab (P) in HER2-positive breast cancer (H plus BC): A Brown University oncology group (BrUOG) study

被引：1
|
作者：
Lopresti, Mary Lorraine [1 ]
Bian, Jessica J. [1 ]
Sakr, Bachir J. [2 ]
Strenger, Rochelle S. [1 ]
Legare, Robert D. [2 ]
Fenton, Mary Anne [1 ]
Witherby, Sabrina M. [1 ]
Dizon, Don S. [1 ]
Pandya, Sonali V. [2 ]
Stuckey, Ashley R. [2 ]
Edmondson, David A. [2 ]
Gass, Jennifer S. [2 ]
Emmick, Christine M. [1 ]
Graves, Theresa A. [1 ]
Cutitar, Marlene [1 ]
Olszewski, Adam J. [1 ]
Sikov, William M. [2 ]
机构：
[1] Lifespan Canc Inst, Providence, RI USA
[2] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-16-19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-16-19
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
    Stacy Moulder
    Hailun Li
    Molin Wang
    William J. Gradishar
    Edith A. Perez
    Joseph A. Sparano
    Michael Pins
    Ximing Yang
    George W. Sledge
    Breast Cancer Research and Treatment, 2010, 119 : 663 - 671
  • [22] Comparison of paclitaxel plus T-DM1 and pertuzumab versus paclitaxel plus trastuzumab and pertuzumab with carboplatin for HER2 overexpressed breast cancer models
    Sun, Yuliang
    Lin, Xiaoqian
    Jepperson, Tyler
    Williams, Casey
    De, Pradip
    Leyland-Jones, Brian
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
    Han, Hyo S.
    Costa, Ricardo
    Armaghani, Avan
    Soyano, Aixa
    Loftus, Loretta
    Soliman, Hatem
    Fridley, Brooke
    Whiting, Junmin
    Cerezo, Aiana
    Rosa, Marilin
    Extermann, Martine
    Khong, Hung
    Czerniecki, Brian
    CANCER RESEARCH, 2022, 82 (04)
  • [24] A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
    Moulder, Stacy
    Li, Hailun
    Wang, Molin
    Gradishar, William J.
    Perez, Edith A.
    Sparano, Joseph A.
    Pins, Michael
    Yang, Ximing
    Sledge, George W.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) : 663 - 671
  • [25] Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland
    Jagiello-Gruszfeld, Agnieszka Irena
    Rosinska, Magdalena
    Meluch, Malgorzata
    Pogoda, Katarzyna
    Niwinska, Anna
    Sienkiewicz, Renata
    Grous, Aleksander
    Winter, Pawel
    Nowecki, Zbigniew I.
    CANCERS, 2022, 14 (05)
  • [26] Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCH-P) in HER2-positive breast cancer: An Indian experience.
    Gogia, Ajay
    Arora, Shalabh
    Deo, S. V. S.
    Mathur, Sandeep
    Sharma, Dayanand
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Cardiotoxicity of weekly trastuzumab (T) plus epirubicin (E) and paclitaxel (P) for HER2-positive locally advanced (LA) and/or metastatic (M) breast cancer (BC): A feasibility phase II study
    Nistico, C.
    Bria, E.
    Cuppone, F.
    Carpino, A.
    Vaccaro, V.
    Barberi, S.
    Sperduti, I.
    Giannarelli, D.
    Cognetti, F.
    Terzoli, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel plus carboplatin plus trastuzumab plus pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
    Masuda, Norikazu
    Ohtani, Shoichiro
    Takano, Toshimi
    Inoue, Kenichi
    Suzuki, Eiji
    Nakamura, Rikiya
    Bando, Hiroko
    Ito, Yoshinori
    Ishida, Kazushige
    Yamanaka, Takashi
    Kuroi, Katsumasa
    Yasojima, Hiroyuki
    Kasai, Hiroi
    Takasuka, Tsuyoshi
    Sakurai, Takaki
    Kataoka, Tatsuki R.
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (01) : 135 - 146
  • [29] Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study
    van Ramshorst, Mette S.
    van Werkhoven, Erik
    Mandjes, Ingrid A. M.
    Schot, Margaret
    Wesseling, Jelle
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Terwogt, Jetske M. Meerum
    Bos, Monique E. M.
    Oosterkamp, Hendrika M.
    Rodenhuis, Sjoerd
    Linn, Sabine C.
    Sonke, Gabe S.
    EUROPEAN JOURNAL OF CANCER, 2017, 74 : 47 - 54
  • [30] A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
    Waks, Adrienne G.
    Desai, Neelam V.
    Li, Tianyu
    Poorvu, Philip D.
    Partridge, Ann H.
    Sinclair, Natalie
    Spring, Laura M.
    Faggen, Meredith
    Constantine, Michael
    Metzger, Otto
    Alberti, Jillian
    Deane, Julia
    Rosenberg, Shoshana M.
    Frank, Elizabeth
    Tolaney, Sara M.
    Krop, Ian E.
    Tung, Nadine M.
    Tayob, Nabihah
    King, Tari A.
    Mittendorf, Elizabeth A.
    Winer, Eric P.
    NPJ BREAST CANCER, 2022, 8 (01)
12345